Abstract:While essential hypertension (HTN) is very prevalent, pulmonary arterial hypertension (PAH) is very rare in the general population. However, due to progressive heart failure, prognoses and survival rates are much worse in PAH. Patients with PAH are at a higher risk of developing supraventricular arrhythmias and malignant ventricular arrhythmias. The latter underlie sudden cardiac death regardless of the mechanical cardiac dysfunction. Systemic chronic inflammation and oxidative stress are causal factors that increase the risk of the occurrence of cardiac arrhythmias in hypertension. These stressful factors contribute to endothelial dysfunction and arterial pressure overload, resulting in the development of cardiac pro-arrhythmic conditions, including myocardial structural, ion channel and connexin43 (Cx43) channel remodeling and their dysfunction. Myocardial fibrosis appears to be a crucial proarrhythmic substrate linked with myocardial electrical instability due to the downregulation and abnormal topology of electrical coupling protein Cx43. Furthermore, these conditions promote ventricular mechanical dysfunction and heart failure. The treatment algorithm in HTN is superior to PAH, likely due to the paucity of comprehensive pathomechanisms and causal factors for a multitargeted approach in PAH. The intention of this review is to provide information regarding the role of Cx43 in the development of cardiac arrhythmias in hypertensive heart disease. Furthermore, information on the progress of therapy in terms of its cardioprotective and potentially antiarrhythmic effects is included. Specifically, the benefits of sodium glucose co-transporter inhibitors (SGLT2i), as well as sotatercept, pirfenidone, ranolazine, nintedanib, mirabegron and melatonin are discussed. Discovering novel therapeutic and antiarrhythmic strategies may be challenging for further research. Undoubtedly, such research should include protection of the heart from inflammation and oxidative stress, as these are primary pro-arrhythmic factors that jeopardize cardiac Cx43 homeostasis, the integrity of intercalated disk and extracellular matrix, and, thereby, heart function.

Stimulation of cardiac beta-adrenoceptors targets connexin 43

THE EXPRESSION OF CONNEXIN 43 IN HUMAN CARDIAC CONDUCTION SYSTEM

Regulation of Gap-Junction Protein Connexin 43 by Β-Adrenergic Receptor Stimulation in Rat Cardiomyocytes

Connexin 43, a new therapeutic target for cardiovascular diseases

[Expression of Connexin in Atrium of Patients with Atrial Fibrillation and Its Signal Transduction Pathway].

Cardiac Β‐adrenergic Receptor Activation Mediates Distinct and Cell Type‐dependent Changes in the Expression and Distribution of Connexin 43

Connexin43 remodeling caused by inhibition of plakophilin-2 expression in cardiac cells

Regulation of β2-adrenergic receptor stimulation on gap junction protein connexin 43 in cultured rat cardiomyocytes

Functional consequences of abnormal Cx43 expression in the heart

Remodelling of gap junctions and connexin expression in diseased myocardium

Connexin 43 and Mitochondria in Cardiovascular Health and Disease

Interacting Network of the Gap Junction (GJ) Protein Connexin43 (Cx43) is Modulated by Ischemia and Reperfusion in the Heart*

Connexin43, A Promising Target to Reduce Cardiac Arrhythmia Burden in Pulmonary Arterial Hypertension

Role of connexin 43 in cardiovascular diseases

Evaluating the role of connexin 43 in congenital heart disease : and the analysis of knockin mouse models

Casein Kinase 1 Phosphomimetic Mutations Negatively Impact Connexin-43 Gap Junctions in Human Pluripotent Stem Cell-Derived Cardiomyocytes

Connexin 43 Phosphorylation: Implications in Multiple Diseases

Effects of angiotensin II on expression of the gap junction channel protein connexin43 in neonatal rat ventricular myocytes

Connexin43 and Myocardial Ischemia-Reperfusion Injury.

Importance of Cx43 for Right Ventricular Function

Regulation of myocardial connexins during hypertrophic remodelling